National Cancer Institute
AstraZeneca agrees on $1.5bn deal with Dizal Pharmaceutical
The company will gain a novel oral treatment for lung cancer
Pfizer and Innovent Biologics agree on deal worth up to $10.5bn
The companies plan to research and develop 12 new cancer treatments
AstraZeneca reports positive phase 3 data for tozorakimab in COPD
COPD affects nearly 400 million people globally and is the third leading cause of death worldwide
One-carbon Therapeutics collaborates with Tempus in cancer treatment
The treatment is currently being evaluated in a phase 1/2 multicentre clinical study
Gilead to acquire Tubulis for up to $5bn
The acquisition builds on Gilead’s oncology pipeline, focused on addressing areas of high unmet need
AstraZeneca’s Imfinzi approved in EU for early gastric and gastro-oesophageal cancers
This is the first and only perioperative immunotherapy approved to treat early gastric cancers
AstraZeneca’s Imfinzi regimen receives positive CHMP opinion for early gastric and gastroesophageal cancer
Gastric cancer is the fifth highest cause of cancer deaths worldwide, with almost a million people diagnosed annually
AstraZeneca and CSPC Pharmaceuticals enter collaboration on weight management therapies
Almost three billion people globally are thought to be either overweight or obese
AstraZeneca announces $15bn investment in Chinese manufacturing and R&D by 2030
The pharma company will be the first global biopharma with end-to-end cell therapy capabilities in China
Vibrant Therapeutics raises $61m in funding to advance intelligent therapeutics pipeline
The financing includes new investors Pfizer Ventures and Apricot Capital, bringing the total capital raised to $100m
AstraZeneca’s Saphnelo demonstrates positive results in systemic lupus erythematosus
Over 3.4 million people globally are affected by SLE, and it is one of the leading causes of death in young women in the US
AstraZeneca’s Enhertu combination approved by FDA for HER2-positive breast cancer
Around one in five breast cancer cases are HER2-positive